Idsk -- Patients with atrial fibrillation who were taking the anticoagulant dabigatran for secondary stroke prevention suffered an ischemic stroke or systemic embolism at a rate similar to patients taking warfarin in a prespecified subgroup analysis of patients from the 2-year RE-LY trial.
